CN104382977A - Special maca composition for women - Google Patents
Special maca composition for women Download PDFInfo
- Publication number
- CN104382977A CN104382977A CN201410653313.7A CN201410653313A CN104382977A CN 104382977 A CN104382977 A CN 104382977A CN 201410653313 A CN201410653313 A CN 201410653313A CN 104382977 A CN104382977 A CN 104382977A
- Authority
- CN
- China
- Prior art keywords
- women
- meyenii walp
- lepidinm meyenii
- estrogen
- maca composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 240000000759 Lepidium meyenii Species 0.000 title claims abstract description 31
- 235000000421 Lepidium meyenii Nutrition 0.000 title claims abstract description 31
- 235000012902 lepidium meyenii Nutrition 0.000 title claims abstract description 31
- 229940011871 estrogen Drugs 0.000 claims description 46
- 239000000262 estrogen Substances 0.000 claims description 46
- 244000068988 Glycine max Species 0.000 claims description 26
- 235000010469 Glycine max Nutrition 0.000 claims description 26
- 230000036541 health Effects 0.000 claims description 25
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 25
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 25
- 235000008696 isoflavones Nutrition 0.000 claims description 25
- 239000000047 product Substances 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 18
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000000284 extract Substances 0.000 claims description 12
- 239000003826 tablet Substances 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000000945 filler Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000314 lubricant Substances 0.000 claims description 6
- 230000002378 acidificating effect Effects 0.000 claims description 5
- 230000002421 anti-septic effect Effects 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 235000013399 edible fruits Nutrition 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 239000000796 flavoring agent Substances 0.000 claims description 5
- 239000000576 food coloring agent Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 239000004014 plasticizer Substances 0.000 claims description 5
- 239000000375 suspending agent Substances 0.000 claims description 5
- 241000219780 Pueraria Species 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- -1 antiseptic Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 208000024891 symptom Diseases 0.000 abstract description 23
- 229940088597 hormone Drugs 0.000 abstract description 14
- 239000005556 hormone Substances 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 13
- 206010025482 malaise Diseases 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 7
- 230000028327 secretion Effects 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 235000003687 soy isoflavones Nutrition 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 206010037660 Pyrexia Diseases 0.000 description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 6
- 230000033228 biological regulation Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 206010022437 insomnia Diseases 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 5
- 235000013402 health food Nutrition 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 206010062767 Hypophysitis Diseases 0.000 description 4
- 208000019255 Menstrual disease Diseases 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 230000002124 endocrine Effects 0.000 description 4
- 230000001076 estrogenic effect Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 208000008035 Back Pain Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000001132 Osteoporosis Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 238000002481 ethanol extraction Methods 0.000 description 3
- 125000004383 glucosinolate group Chemical group 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 210000003016 hypothalamus Anatomy 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003821 menstrual periods Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 208000035824 paresthesia Diseases 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 241000167854 Bourreria succulenta Species 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 244000060011 Cocos nucifera Species 0.000 description 2
- 235000013162 Cocos nucifera Nutrition 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000000940 FEMA 2235 Substances 0.000 description 2
- 206010017062 Formication Diseases 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010041349 Somnolence Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 206010048222 Xerosis Diseases 0.000 description 2
- 210000004100 adrenal gland Anatomy 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000019693 cherries Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- SEBIKDIMAPSUBY-ARYZWOCPSA-N Crocin Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)C(C)=CC=CC(C)=C\C=C\C=C(/C)\C=C\C=C(C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1)O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SEBIKDIMAPSUBY-ARYZWOCPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010057315 Daydreaming Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QSJXEFYPDANLFS-UHFFFAOYSA-N Diacetyl Chemical group CC(=O)C(C)=O QSJXEFYPDANLFS-UHFFFAOYSA-N 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- XINCECQTMHSORG-UHFFFAOYSA-N Isoamyl isovalerate Chemical compound CC(C)CCOC(=O)CC(C)C XINCECQTMHSORG-UHFFFAOYSA-N 0.000 description 1
- 206010024419 Libido decreased Diseases 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- KWKVAGQCDSHWFK-VNKDHWASSA-N Methyl sorbate Chemical compound COC(=O)\C=C\C=C\C KWKVAGQCDSHWFK-VNKDHWASSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 206010033122 Ovarian atrophy Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 238000003723 Smelting Methods 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 230000037118 bone strength Effects 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229940109262 curcumin Drugs 0.000 description 1
- 235000012754 curcumin Nutrition 0.000 description 1
- 239000004148 curcumin Substances 0.000 description 1
- 201000010251 cutis laxa Diseases 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003001 depressive effect Effects 0.000 description 1
- RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 description 1
- 229960004976 desogestrel Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 102000015694 estrogen receptors Human genes 0.000 description 1
- 108010038795 estrogen receptors Proteins 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000009627 gardenia yellow Substances 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000022168 hypermenorrhea Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 206010027175 memory impairment Diseases 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229930189775 mogroside Natural products 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000036565 night sweats Effects 0.000 description 1
- 206010029410 night sweats Diseases 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
- 230000001009 osteoporotic effect Effects 0.000 description 1
- 231100001043 ovarian atrophy Toxicity 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- GJLNWLVPAHNBQN-UHFFFAOYSA-N phenyl 4-hydroxybenzoate Chemical compound C1=CC(O)=CC=C1C(=O)OC1=CC=CC=C1 GJLNWLVPAHNBQN-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000004300 potassium benzoate Substances 0.000 description 1
- 235000010235 potassium benzoate Nutrition 0.000 description 1
- 229940103091 potassium benzoate Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 235000010956 sodium stearoyl-2-lactylate Nutrition 0.000 description 1
- KNYAZNABVSEZDS-UHFFFAOYSA-M sodium;2-octadecanoyloxypropanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C([O-])=O KNYAZNABVSEZDS-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 238000004383 yellowing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a special maca composition for women, belonging to the technical field of biological medicines. The special maca composition comprises a maca product and soy isoflavone. The special maca composition disclosed by the invention has the beneficial effects that female hormones in different woman bodies can be rapidly and effectively supplemented or adjusted, multiple unwell symptoms or diseases of women brought to the body due to lack of in-vivo female hormones or excessive female hormone are overcome or prevented, and a side effect for inhibiting in-vivo female hormone secretion is avoided.
Description
Technical field
The invention belongs to biomedicine technical field, be specifically related to the maca composition that a kind of women is special.
Background technology
Estrogen has inseparable relation, the many variations of estrogen with the health in women's all one's life, always shows outstanding especially with it in women.
People knows from experience the hormone of secretion more than 75 kinds, and they play respective role in human body.The women that in body, estrogen concentration is high, the of the same age women lower than estrogen concentration in body seems young a lot.21-22 year is the noontide in youth, is also the period at the most peak of excretory system function.Women's estrogen starts to reduce for 25 years old, and in body, hormonal secretory volume reduces year by year with the speed of decline 15% in every 10 years, and each organ-tissue of human body starts aging atrophy gradually, and skin is obviously dull, listless.When 60 years old, women's estrogen hormone secretion amount only has at an early age about 1/5.
During shortage estrogen, women has following performance:
1, pubes and axillary trichomadesis, hyposexuality, vaginal secretions reduces, and occurs pain during sexual intercourse, the generation of the minimizing that then result in sexual life number of times or the emotion detesting sexual life.
2, insomnia forgetfulness, vexed meaning is dry, insomnia, dreaminess, tired, headache.The method of hypnosis in evening is all used up, and still can't fall asleep.Daytime is absent minded, sleepy drowsiness, has a strong impact on daily life.Have a dizzy spell, xerostomia, there is burn feeling in throat, and thought is not easily concentrated, and nervous exciting, emotion irascible temperament complicated and changeable, and insomnia key is forgotten, and skin is numb itches, and sometimes has formication.
3, menoxenia, this is one of harm of common climacteric syndrome, and often show as menstrual blood volume and reduce gradually, the cycle extends gradually, and menstrual period shorten, so that menolipsis gradually.But sometimes also there will be hyper-menorrhea, and occur with situations such as a large amount of clots.Menstruation is not be exactly postpone in advance, and menstrual period are long.
4, skin aging, stature are out of shape, and enter into the climacteric period ovarian atrophy, dyssecretosis of woman causes cutis laxa, and day by day coarse, corse sweat pore yellowing of the skin, speckle, wrinkle increase, the slack and undisciplined distortion of waist abdomen breast.
5, hectic fever night sweat, the hazard ratio of climacteric syndrome more typically shows as hectic fever, sometimes hot and sometimes cold, goes out profuse sweating, sometimes has dizziness, and every day can occur several times or tens times, and many at night-time attack, even occurs stuffy, the symptom such as to breathe hard.
6, osteoporosis: bone strength weakens, fracture susceptibility increases, and bone metabolism negative balance, average every day loses 50mg calcium, often has lumbago and skelalgia, backache, and namely height attenuating etc., slightly firmly fracture.
7, premature menopause: uterus, ovary, hypophysis and hypothalamus, all may there is amenorrhea in any one link generation obstacle.
In the past, medicine controversies in hormone replacement in the elderly was the liberator of many climacteric womens always, even by numerous doctor and scientist, was described as the miraculous cure that can remain youthful forever.Only in the U.S., just there is climacteric women more than 40% always at drug administration estrogen.A lot of people starts to take when menolipsis, uses 70 ~ 80 years old always.
Recent one is found by the scientific experimentation of U.S. Government support, medicine controversies in hormone replacement in the elderly is more harm than good, verified, is used alone medicine estrogen for a long time, the probability of suffering from the disease such as cardiovascular disease and breast carcinoma increases greatly, and carcinoma of endometrium incidence rate can be made to increase by 5 ~ 7 times.This report allows thousands of just astonished and angry the estrogenic women of drug administration.
Discovery soybean isoflavone is studied through expert, soybean isoflavone is by the effective ingredients in plant extracted in crude soya bean, because it and estrogenic molecular structure are closely similar, can combine with the estrogen receptor in women's body, estrogen is played to the effect of two-ways regulation, thus " phytoestrogen " soybean isoflavone that is otherwise known as have improve skin quality, improve discomfort in menstrual period, defying age, delay climacteric, alleviate climacteric uncomfortable, improve the effects such as life quality, prevention of osteoporosis, breast carcinoma, alzheimer disease, cardiovascular disease.But long-term dependence is taken soybean isoflavone and is improved uncomfortable symptom as ectogenic estrogen, existence makes women self produce estrogenic Functional tissue can be suppressed the hidden danger of even degenerating, the effect of soybean isoflavone is being taken a fancy to simultaneously by a lot of consumer, also start to pay close attention to long-term taking soybean isoflavone whether safety, the ectogenic estrogen of soybean isoflavone suppresses the problems such as the side effect of body inner estrogen secretion.
Lepidinm meyenii Walp and Maca extract can be used for treating female dimacteric syndrome traditionally, show through modern study, the alkaloid contained in Lepidinm meyenii Walp acts on hypothalamus and hypophysis cerebri, has the function of endocrine regulation gland as adrenal gland, thyroid, pancreas, ovary etc., thus can balance hormone.And some other compositions in Lepidinm meyenii Walp can alleviate hypothalamus and hypophysis cerebri hyperfunctioning as exogenous hormone substitute, because alkaloid wherein also can supplement the deficiency of estradiol production.In addition, in Lepidinm meyenii Walp, sterol and Saponin can as the precursor of multiple hormone as steroid hormone, and in Lepidinm meyenii Walp, glucosinolate and benzyl isothiocyanate are also relevant with endocrine.Lepidinm meyenii Walp and Maca extract have following effect for women:
1, endocrine regulation; climacteric syndrome---the multiple alkaloid of Lepidinm meyenii Walp can regulate the functions such as adrenal gland, pancreas, ovary in antagonism; hormone level in balanced body, physiological function can be nursed one's health and repair to abundant taurine, protein etc., improves QI and blood and alleviate menopause syndrome.
2, strengthen immunologic function, resisting fatigue, anti-anemia action---Lepidinm meyenii Walp is containing the ferrum of higher amount, and protein, aminoacid, mineral zinc etc. can help firm immune system, promotes body premunition, to resisting fatigue, improves Anemia.Therefore Lepidinm meyenii Walp and Maca extract are that a kind of long-term taking security performance is good, almost be free from side effects, fundamentally solve the green estrogen regulator of estrogen balance in women's body, can not be directly quick but exist, improve the serum estrogen level in women's body quantitatively.Thus to when improving not in time due to the multiple malaise symptoms in women's body caused by estrogen shortage, there is the problem that efficiency for the treatment of or keep healthy is lower.
Therefore need to invent a kind of efficiency higher, long-term taking is safer, be free from side effects or side effect less, the efficient estrogen health food (two-ways regulation agent) with the green-series of stronger dual regulation is used as women's special health food, be supplied to all ages and classes specially, the estrogen had in body lacks or surplus women in various degree chooses edible, can fast and effeciently supplement the estrogen regulating or regulate in different women's body by Enough, effectively help women to overcome or anti-smelting owing to lacking in body that estrogen or estrogen are superfluous, above-mentioned all malaise symptoms of bringing or disease are very necessary, great meaning is had for helping the life of women's safety and Health in all one's life.
Summary of the invention
The object of this invention is to provide the maca composition that a kind of women is special, this maca composition fast and effeciently can supplement the estrogen regulating or regulate in different women's body.
The technical solution used in the present invention is the special maca composition of a kind of women, comprises Lepidinm meyenii Walp goods and soybean isoflavone.
The mass ratio of described Lepidinm meyenii Walp goods and described soybean isoflavone is 1 ~ 200:1.
The mass ratio of described Lepidinm meyenii Walp goods and described soybean isoflavone is 10 ~ 160:1.
Described Lepidinm meyenii Walp goods comprise pueraria root powder, Maca extract.Particularly preferred, described Maca extract is Lepidinm meyenii Walp water extract or Lepidinm meyenii Walp ethanol extraction.
The present invention also provides the application of a kind of described maca composition in preparation adjustment estrogen health product.
The present invention also provides a kind of health product, comprises pharmaceutically acceptable adjuvant and described maca composition.
The dosage form of described health product is tablet, capsule, granule, powder or liquid preparation.
Described pharmaceutically acceptable adjuvant is selected from one or more the mixture in Fruit powder, edible essence, sweeting agent, acidic flavoring agent, filler, lubricant, antiseptic, suspending agent, food coloring, diluent, emulsifying agent, disintegrating agent or plasticizer.
As preferably, Fruit powder is a kind of or both the above mixture in orange powder, orange powder, Fructus Citri Limoniae powder, cherry powder, apple powder or coconut palm powder.But those skilled in the art think that feasible Fruit powder is all within protection scope of the present invention, and Fruit powder kind is not limited thereto, and the present invention does not limit at this.
As preferably, edible essence is a kind of or both the above mixture in flavoring orange essence, orange essence, Fructus Citri Limoniae essence, cherry essence, Mentholum, apple essence or coconut palm essence.But those skilled in the art think that feasible edible essence is all within protection scope of the present invention, and edible essence kind is not limited thereto, and the present invention does not limit at this.
In order to increase the mouthfeel of health product, sweeting agent also can be added to increase the sugariness of health product.As preferably, sweeting agent is a kind of or both the above mixture in sucralose, acesulfame potassium, aspartame or mogroside.But those skilled in the art think that feasible sweeting agent is all within protection scope of the present invention, and sweeting agent kind is not limited thereto, and the present invention does not limit at this.
As preferably, acidic flavoring agent is a kind of or both the above mixture in citric acid, malic acid, lactic acid or citric acid.But those skilled in the art think that feasible acidic flavoring agent is all within protection scope of the present invention, and acidic flavoring agent kind is not limited thereto, and the present invention does not limit at this.
Filler refers to the weight and volume increasing tablet, is beneficial to the adjuvant of tabletting.Filler as tablet requires that mobility, compressibility are good, and adhesion is strong, has larger saturation to medicine.As preferably, filler is a kind of or both the above mixture in fructose, sugar alcohols, sucrose, starch, pregelatinized Starch, microcrystalline Cellulose or dextrin.But those skilled in the art think that feasible disintegrating agent is all within protection scope of the present invention, and filler kind is not limited thereto, and the present invention does not limit at this.
Lubricant refers to the adjuvant that can reduce frictional force between tablet and die wall, makes tabletting difficulty to prevent frictional force large, and when can make tabletting, pressure distribution is even, and makes the even density of tablet, can also improve the outward appearance of tablet, makes tablet surface light, smooth.As preferably, lubricant is a kind of or both the above mixture in Pulvis Talci, magnesium stearate, silicon dioxide or stearic acid.But those skilled in the art think that feasible lubricant is all within protection scope of the present invention, and lubricant kind is not limited thereto, and the present invention does not limit at this.
As preferably, antiseptic is a kind of or both the above mixture in sodium benzoate, Potassium Benzoate, sorbic acid methyl ester, ethylparaben or P-hydroxybenzoic acid phenyl ester.But those skilled in the art think that feasible antiseptic is all within protection scope of the present invention, and antiseptic kind is not limited thereto, and the present invention does not limit at this.
As preferably, suspending agent is a kind of or both the above mixture in sodium carboxymethyl cellulose, sodium alginate or Cera Flava.But those skilled in the art think that feasible suspending agent is all within protection scope of the present invention, and suspending agent kind is not limited thereto, and the present invention does not limit at this.
As preferably, food coloring is a kind of or both the above mixture in caramel color, Gardenia Yellow, curcumin or chlorophyll.But those skilled in the art think that feasible food coloring is all within protection scope of the present invention, and food coloring kind is not limited thereto, and the present invention does not limit at this.
As preferably, diluent a kind of or both above mixture that to be edible vegetable oil, propylene glycol or molecular weight be in the Polyethylene Glycol of 400 ~ 6000.But those skilled in the art think that feasible diluent is all within protection scope of the present invention, and diluent kind is not limited thereto, and the present invention does not limit at this.
As preferably, emulsifying agent is S-40, sodium stearoyl lactate/calcium, diacetyl tartarate monoglyceride, sucrose fatty acid ester, molecular weight be 400 ~ 6000 Polyethylene Glycol or distillation monoglyceride in a kind of or both above mixture.But those skilled in the art think that feasible emulsifying agent is all within protection scope of the present invention, and emulsifier is not limited thereto, and the present invention does not limit at this.
The Main Function of disintegrating agent is to eliminate because binding agent or the adhesion that forms tablet by pressurizeing make the rapid disintegrate of tablet, makes tablet can play drug effect rapidly.As preferably, disintegrating agent is a kind of or both the above mixture in dried starch, carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone or sodium carboxymethyl cellulose.But those skilled in the art think that feasible disintegrating agent is all within protection scope of the present invention, and filler kind is not limited thereto, and the present invention does not limit at this.
As preferably, plasticizer is a kind of or both the above mixture in glycerol, sodium carboxymethyl cellulose, sorbitol or oleamide sodium sulfonate.But those skilled in the art think that feasible plasticizer is all within protection scope of the present invention, and plasticizer kind is not limited thereto, and the present invention does not limit at this.
The present invention also provides a kind of preparation method of described health product, gets described pharmaceutically acceptable adjuvant and the mixing of described maca composition, to obtain final product.
The invention provides maca composition and application, health product and preparation method thereof.This maca composition comprises Lepidinm meyenii Walp goods and soybean isoflavone.Result of the test shows, maca composition provided by the invention more fast and effeciently can be supplemented and be regulated or regulate estrogen in different women's body, improves women and overcomes or prevent and treat the above-mentioned all malaise symptoms or disease that bring owing to lacking estrogen or estrogen surplus in body.Relative to Chinese medicine single dose, maca composition provided by the invention has significant synergies.
Beneficial effect of the present invention is:
(1) Lepidinm meyenii Walp contains 4 kinds of alkaloids, glucosinolate, multivitamin as protein, aminoacid, polysaccharide, mineral and multiple natural plant active component.These compositions have been proved relevant with Lepidinm meyenii Walp resisting fatigue, antidepressant, raising fertility, endocrine regulation.Containing two kinds of unique active components of plants-Glucosinolates (Glucosinolates) in Lepidinm meyenii Walp: macamide and Lepidinm meyenii Walp alkene, the hormonal system of women can be allowed to restore balance, thus " from inside to outside, treating both the principal and secondary aspects of a disease ", with Lepidinm meyenii Walp goods for Main Ingredients and Appearance, be equipped with the female flavone of large beans, making series of products can select edible for the multiple malaise symptoms improved caused by different women's body endogenous cause of ill estrogen shortages or surplus provides the special Lepidinm meyenii Walp health foodstuff series of different types of women, the hormonal system of women not only can be made efficiently to restore balance, improve the multiple malaise symptoms that different women brings because of non-equilibrium of hormones, edible Lepidinm meyenii Walp can by increasing the vigor of health and each organ simultaneously, fundamentally strengthen the body constitution of female body, do not deposit and make women self produce estrogenic Functional tissue to be after consumption suppressed the hidden danger of even degenerating, therefore be a kind of side effect not suppressing body inner estrogen to be secreted, can the health food of safety of long-term taking, simultaneously also for women increases the functional food of power and beauty health.
(2) health product of the present invention utilize Lepidinm meyenii Walp active ingredient effective stimulus female body hypophysis, make women rely on self secretion estrogen in body to reach the dynamic equilibrium of estrogen simultaneously, general women is along with the increase at age, the high women of estrogen deficiency extent in therefore middle aged and aged women or body that successively decreases year by year can select and is equipped with the special Lepidinm meyenii Walp health food of the more women of soybean isoflavone Ingredient Amount containing the concentrated extract that Lepidinm meyenii Walp composition is higher and eats for self estrogen, quick adjustment body endogenous cause of ill estrogen balances, and improves the malaise symptoms of health.When estrogen is in a basic balance in vivo, progressively select containing the former powder of the Lepidinm meyenii Walp that Lepidinm meyenii Walp composition is lower and to be equipped with soybean isoflavone quantity Ingredient Amount lower or do not eat containing the Lepidinm meyenii Walp health food of soybean isoflavone, women is progressively reached and only relies on Lepidinm meyenii Walp composition to stimulate the hormone secretion of self organ just can make the maintenance dynamic equilibrium of the estrogen in health.
(3) for the women of the multiple malaise symptoms caused by women's body endogenous cause of ill estrogen surplus, edible health product of the present invention, the estrogen balance in energy quick adjustment body, improves the malaise symptoms of health.
Detailed description of the invention
For making those skilled in the art understand production technology of the present invention and technique effect in detail, introduce application of the present invention and technique effect further with concrete production instance below.
Embodiment 1:
Take pueraria root powder 8000 grams and soybean isoflavone 100 grams, mix homogeneously, adds appropriate magnesium stearate, tabletting, to obtain final product.Wherein, specification is 0.5 gram/piece.
Embodiment 2:
Take pueraria root powder 16000 grams and soybean isoflavone 100 grams, mix homogeneously, adds appropriate micropowder silica gel, filled capsules, to obtain final product.Wherein, specification is 0.3 gram/.
Embodiment 3:
By Lepidinm meyenii Walp coarse crushing, add the soak by water 3 times of 10 times of weight, merge 3 extracting solution, concentrated, dry, obtain Lepidinm meyenii Walp water extract.
Take Lepidinm meyenii Walp water extract 1000 grams and soybean isoflavone 100 grams, mix homogeneously, adds appropriate amount of starch, orange essence and aspartame, tabletting, to obtain final product.Wherein, specification is 0.7 gram/piece.
Eat to Mrs climacteric of one 50 years old, this Ms does not have or have little menstrual blood volume every month, there is multiple comparatively serious climacteric syndrome shape, doctor opens the female alcohol sheet of desogestrel and GENGNIANAN, within 21 days, stop to take again for 7 days, take period to tired and irritated uncomfortable in chest, hectic fever, palpitation and short breath, emotional, etc. symptom slightly improve, but to insomnia, dreaminess, the symptom such as weak, blood pressure is high without improvement, have after taking medicine easily to send out and feel sick, uncomfortable situation, and therapeutic effect is unstable, above-mentioned uncomfortable symptom fast quick-recovery again after drug withdrawal.
Change and take the special maca composition of the women that makes as stated above, sooner or later each edible once, each edible 4, after one week, significantly improve rapidly the insomnia of this Ms, dreaminess, tired and irritated breast is vexed, hectic fever, palpitation and short breath, emotional, weak, the symptoms such as blood pressure is high, all symptoms uncomfortable on this female body after one month all obtain obviously stable improvement, and maintain a small amount of menstruation every month, keep having a surplus one year so far always, the spirit of this female's soil and the muscle power of health are obviously promoted simultaneously, the ruddy exquisiteness of the colour of skin of body skin.
Embodiment 4:
By Lepidinm meyenii Walp coarse crushing, the mass percent thick fog adding 10 times of weight is the alcohol reflux 2 times of 90%, merges 2 extracting solution, concentrated, dry, obtains Lepidinm meyenii Walp ethanol extraction.
Take Lepidinm meyenii Walp ethanol extraction 2000 grams and soybean isoflavone 100 grams, mix homogeneously, adds suitable amount of sucrose and dextrin, granulates, obtains granule.Wherein, specification is 2 grams/bag.
In donor, 28 years old women of estrogen surplus eats, sooner or later each edible once, each edible one bag.After one week, improve rapidly this Ms's menoxenia, the symptom of sick warp, after taking 2 months, also make the comedo of this women's facial significantly reduce, significantly improve the problem of this women's facial pachylosis.
Embodiment 5:
By Lepidinm meyenii Walp coarse crushing, add the soak by water 2 times of 12 times of weight, merge 2 extracting solution, concentrated, dry, obtain Lepidinm meyenii Walp water extract.
Take Lepidinm meyenii Walp water extract 100000 grams and soybean isoflavone 1000 grams, mix homogeneously, adds suitable quantity of water, flavoring orange essence, caramel color, sodium benzoate, and mixing, fine straining, fill, obtains beverage.Wherein, specification is 300 grams/tank.
For effectively verifying technique effect of the present invention, the following test of special do:
Estrogen lacks, generally can show the aspects such as cardiovascular, genitourinary system, osteoporosis and autonomic nervous dysfunction, be embodied in: xerosis cutis pruritus, formication, paraesthesia (often having twinge, numbness, tinnitus), Tidal fever with perspiration, often insomnia, anxiety, irritability, produce Depressive mood, occur that sub-health state is (as dizziness, headache, lassitude and weak, back and joint aches, there is osteoporotic symptom, hypomnesis, cardiopalmus, fluctuation of blood pressure, urinary system discomfort), menoxenia, sexual life difficulty etc.
Estrogen is superfluous, generally can show hyperovaria, adenohypophysis tumor, cerebral tissue hypertrophy occurs, hyperthyroidism, liver cirrhosis etc.
Select that there is estrogen to lack or the women 100 of surplus, the age 40-70 year, edible various embodiments of the present invention products obtained therefrom respectively, contrasts with the product be only made up of Lepidinm meyenii Walp or soybean isoflavone.Edible time is 1 month.Wherein, edible various embodiments of the present invention product is to the symptom lacking estrogen women, and can effectively improve various symptom, be mainly reflected in and can effectively improve the aspects such as menoxenia, xerosis cutis, Tidal fever with perspiration, lassitude and weak, effective percentage reaches 95%, and invalid 5%.The symptom of the product be only made up of Lepidinm meyenii Walp or soybean isoflavone to the women lacking estrogen is improved not too obvious.
Edible various embodiments of the present invention product is to the symptom of the superfluous women of estrogen, and also have clear improvement, its effective percentage reaches 70%.The symptom of the product be only made up of Lepidinm meyenii Walp or soybean isoflavone to the superfluous women of estrogen is not improved substantially.
Finally it should be noted that, above embodiment is the unrestricted technical scheme of the present invention in order to explanation only, although with reference to above-described embodiment to invention has been detailed description, those skilled in the art are to be understood that, still can modify to the present invention or equivalent replacement, and not departing from any modification or partial replacement of the spirit and scope of the present invention, it all should be encompassed in right of the present invention.
Claims (9)
1. the maca composition that women is special, is characterized in that: comprise Lepidinm meyenii Walp goods and soybean isoflavone.
2. the maca composition that a kind of women according to claim 1 is special, is characterized in that: the mass ratio of described Lepidinm meyenii Walp goods and described soybean isoflavone is 1 ~ 200:1.
3. the maca composition that a kind of women according to claim 2 is special, is characterized in that: the mass ratio of described Lepidinm meyenii Walp goods and described soybean isoflavone is 10 ~ 160:1.
4. the maca composition that a kind of women according to any one of claim 1-3 is special, is characterized in that: described Lepidinm meyenii Walp goods comprise pueraria root powder, Maca extract.
5. the maca composition according to any one of claim 1-4 regulates the application in estrogen health product in preparation.
6. health product, is characterized in that: comprise pharmaceutically acceptable adjuvant and the maca composition according to any one of claim 1-4.
7. health product according to claim 6, is characterized in that: the dosage form of described health product is tablet, capsule, granule, powder or liquid preparation.
8. health product according to claim 6, is characterized in that: described pharmaceutically acceptable adjuvant is selected from one or more the mixture in Fruit powder, edible essence, sweeting agent, acidic flavoring agent, filler, lubricant, antiseptic, suspending agent, food coloring, diluent, emulsifying agent, disintegrating agent or plasticizer.
9. the preparation method of health product according to any one of claim 6-8, is characterized in that: get described pharmaceutically acceptable adjuvant and the mixing of the maca composition according to any one of claim 1-4, to obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410653313.7A CN104382977A (en) | 2014-11-17 | 2014-11-17 | Special maca composition for women |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410653313.7A CN104382977A (en) | 2014-11-17 | 2014-11-17 | Special maca composition for women |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104382977A true CN104382977A (en) | 2015-03-04 |
Family
ID=52601002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410653313.7A Pending CN104382977A (en) | 2014-11-17 | 2014-11-17 | Special maca composition for women |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104382977A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103404845A (en) * | 2013-05-27 | 2013-11-27 | 胡安然 | Special diet for insomnia patients |
| KR20140012210A (en) * | 2001-06-08 | 2014-01-29 | 애브비 바이오테크놀로지 리미티드 | Methods of administering anti-TNFα antibodies |
| CN104095231A (en) * | 2014-06-20 | 2014-10-15 | 云南省药物研究所 | Health-care product containing mair conditioning unita, dendrobium and American ginseng and preparation method thereof |
| CN104223304A (en) * | 2014-09-30 | 2014-12-24 | 无锡康顿生物科技有限公司 | Product capable of relieving nerves and improving menopausal symptoms and preparation method thereof |
-
2014
- 2014-11-17 CN CN201410653313.7A patent/CN104382977A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140012210A (en) * | 2001-06-08 | 2014-01-29 | 애브비 바이오테크놀로지 리미티드 | Methods of administering anti-TNFα antibodies |
| CN103404845A (en) * | 2013-05-27 | 2013-11-27 | 胡安然 | Special diet for insomnia patients |
| CN104095231A (en) * | 2014-06-20 | 2014-10-15 | 云南省药物研究所 | Health-care product containing mair conditioning unita, dendrobium and American ginseng and preparation method thereof |
| CN104223304A (en) * | 2014-09-30 | 2014-12-24 | 无锡康顿生物科技有限公司 | Product capable of relieving nerves and improving menopausal symptoms and preparation method thereof |
Non-Patent Citations (5)
| Title |
|---|
| 余龙江等: "《国际良种：药食两用植物MACA》", 31 December 2006, 华中科技大学出版社 * |
| 刘志胜等: "大豆异黄酮及其生理功能研究进展", 《食品工业科技》 * |
| 尹子娟: "玛咖的营养成分及功效研究进展", 《云南农业科技》 * |
| 段柯兆等: "《玛咖》", 31 October 2014, 云南科技出版社 * |
| 赵齐川: "《豆制品加工技艺 第2版》", 30 October 2013, 金盾出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101757248A (en) | Compound donkey-hide gelatin cake for woman | |
| KR101964841B1 (en) | Composition for relieving menopausal symptom | |
| CN104288461A (en) | Ginseng cornu cervi tea traditional Chinese medicine decoction piece combined preparation, as well as preparation method and combined package thereof | |
| CN102640829A (en) | Tea paste with myocardial ischemia function improving function and preparation method of tea paste | |
| CN102846906A (en) | Medicament for treating premature ovarian failure and preparation method thereof | |
| CN102613416B (en) | Feed additive for producing zinc-enriched quail eggs | |
| JP7108325B2 (en) | A pharmaceutical composition for prevention or treatment of gynecological diseases containing an ear mushroom extract as an active ingredient | |
| CN103520302B (en) | Sea-buckthorn leaf anti-fatigue capsule and preparation method thereof | |
| CN104605352A (en) | Maca and roxburgh rose nutrition composition for promoting body blood circulation and warmly invigorating kidney yang as well as preparation method and application thereof | |
| CN102462787B (en) | Chinese medicine composition for treating hypertension and improving hyperlipidemia and preparation method of Chinese medicine composition | |
| CN106036880B (en) | A kind of composition and its application and the healthy food being made from it for alleviating dysmenorrhea | |
| CN102266427B (en) | Cartialgenous and angelica wine for maintaining beauty and keeping young as well as preparation method and application thereof | |
| CN104382977A (en) | Special maca composition for women | |
| TWI728304B (en) | Yin nourishing and kidney tonifying composition and its preparation method and application | |
| CN103463456A (en) | Traditional Chinese medicine composition and preparation method thereof | |
| CN103432274B (en) | Medicament for treating migraine and preparation method thereof | |
| CN102727546B (en) | Health-promoting composition for treating insomnia and cardiovascular/cerebrovascular diseases | |
| CN104758431A (en) | Tablet for improving arrhythmia and preparation method of tablet | |
| CN105342923A (en) | Lipstick for preventing lip chapping and its preparation method | |
| CN104256582A (en) | Health product formula for relieving various symptoms of menopause women | |
| CN105106146B (en) | Vertical compression tablet containing Chinese medicine lotus seeds and oyster shell | |
| CN107095908A (en) | It is a kind of to treat pharmaceutical composition of impotence and preparation method thereof, preparation and application | |
| CN114343175A (en) | Deer fetus paste instant powder | |
| CN104857286A (en) | Liquor for tonifying qi, invigorating yang and replenishing essence | |
| CN116114778A (en) | Food composition for promoting testosterone level and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150304 |